OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.23 · Revenue $215120.00 · 1 analysts
Est. EPS $-0.23 · Revenue $447280.00 · 2 analysts
Est. EPS $-0.91 · Revenue $882800.00 · 3 analysts
Est. EPS $-0.24 · Revenue $303700.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $4.1M | +115.6% | +646.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-50.2M | +17.2% | -162.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +4.7% | -88.1% | +103.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -754.1% | +76.8% | +85.2% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1238.5% | +61.6% | +64.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-25.4M | -19.5% | -21.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -625.6% | +44.6% | +83.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -11.1% | +62.8% | +57.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.27x | -21.6% | -21.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $25.8M | -26.6% | -27.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.65 vs -1.15 | -44.1% | -0.31 vs -0.23 | -33.4% |
| Revenue Surprise | $4.1M vs $3.2M | +25.7% | $239000 vs $215120 | +11.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | SILVERMAN LOU | director | Common Stock, no par value | D | 7,700 | $5.69 |
| Jul 1, 2026 | Last Andrew J. | director | Common Stock, no par value | D | 7,700 | $5.69 |
| Jul 1, 2026 | Arno Andrew | director | Common Stock, no par value | D | 12,100 | $5.69 |
| Jun 11, 2026 | SILVERMAN LOU | director | Common Stock, no par value | A | 26,943 | — |
| Jun 11, 2026 | Last Andrew J. | director | Common Stock, no par value | A | 26,943 | — |
Gabrielle Woody: Welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics' second quarter 2026 results. If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics' Investor Relations page at investors.imdxinc.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics' President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SEC filings, including the company's most recent Form 10-K and subsequent Form 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note the forward-looking statements made during today's call speak only to the date they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs. Joshua Riggs: Thanks, Gabby. It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx. We have 3 brief but promising takeaways today in our shareholder letter. The first is that after 3 years of rigorous kitted product development, we believe that we are seeing the light at the end of the tunnel on having a regulated product. Back in July, we got our additional information letter from the FDA. It's a normal part of the Class II process where they ask for some additional data and clarification on intended use as part of their review. Since submitting back in March, we've about tripled the amount of samples collected in the study and feel good about addressing all their questions and comments. Prior to submitting our next data package, we are going to have an SIR meeting with the FDA. This meeting is a lot like the Q-Sub process where you get direct and written feedback on your planned approach. It's an opportunity for both parties to make sure there is clear understanding on what is needed to get through to authorization and clear up any potential misunderstandings. Once we have the green light from them, the next steps are pretty straightforward. We package it all up, hit submit and wait for their response. Since March, we have been pleased with the timeliness of FDA's engagement. We continue to target receipt of FDA marketing authorization later this year with the caveat that the timing of government agency review …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Joshua Riggs | President, Chief Executive Officer & Director | USD 662,787 | Male | 1983 | Active |
Ekkehard Schutz | Chief Science Officer | USD 552,014 | — | — | Active |
Andrea Susan James | Chief Financial Officer | USD 536,578 | Female | 1982 | Active |
James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer | USD 303,253 | Male | 1996 | Active |
Yuh-Min Chiang | Chief Technology Officer | — | Male | — | Active |
Steven Tahmooressi | Vice President of Marketing | — | Male | — | Active |
Sandra O'Donald | Senior Vice President of Business Operations | — | Female | — | Active |
Peter Hong | Vice President, General Counsel & Secretary | — | Male | — | Active |
Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | — | — | 1953 | Active |
Paul R. Billings FACP | Consulting Chief Medical Officer | — | — | 1952 | Active |
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring.
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026.
Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions New study signals GraftAssure™ assay's market expansion opportunity as drugs to treat organ rejection work their way through clinical trials iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) ("iMDx") today highlighted the publication of a new study in The Lancet Regional Health – Europe, part of the Lancet Group, demonstrating the potential role of donor-derived cell-free DNA (dd-cfDNA) monitoring to help guide treatment decisions for kidney transplant patients.
